Gossamer Bio price target raised to $12 from $9 at Oppenheimer

Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Gossamer Bio (GOSS) to $12 from $9 and keeps an Outperform rating on the shares following quarterly results. Approaching the February 2026 PROSERA topline readout, the firm continues to see success given PROSERA’s baseline population and positive Phase 2 TORREY data increasing the likelihood of achieving statistically significant 6MWD. Additionally, the first clinical site from Phase 3 SERANATA/PH-ILD has been activated, with results expected in 2027.